<?xml version="1.0" ?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" 
 xmlns:mml="http://www.w3.org/1998/Math/MathML">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text>
		<front/>
		<body/>
		<back>
<listBibl>
	<bibl><title level="m">Box 1. Drug safety monitoring and consumer protection</title> <author>........................................................................</author>. <biblScope unit="page">12</biblScope></bibl>
	<bibl>Box <biblScope unit="issue">2</biblScope>. <title level="a">Drug coverage in selected provinces and in the federal Non-insured Health Benefits programme20 Box3 .Formulary listing processes used in selected drug coverage schemes</title> <author>..........................................</author>.<biblScope unit="page">23</biblScope></bibl>
	<bibl><author>Box 4</author>. <title level="a">Evidence of the impact of formulary listing on consumption patterns</title><author>.........................................</author>. <biblScope unit="page">27</biblScope></bibl>
	<bibl>Box <biblScope unit="volume">5</biblScope>. <title level="a">Cost-sharing arrangements in selected provincial drug plans</title> <author>......................................................</author>. <biblScope unit="page">33</biblScope></bibl>
	<bibl>Box <biblScope unit="volume">6</biblScope>. <title level="a">Canadian evidence on the impact of cost-sharing on drug use</title><author>.....................................................</author>. <biblScope unit="page">34</biblScope></bibl>
	<bibl><title level="m">Box 7. Developing a new national strategy for pharmaceuticals</title> <author>in Canada ............................................</author>. <biblScope unit="page">37</biblScope></bibl>
	<bibl><author>Box 8. Cross-border trade ........................................................................................................................</author>. <biblScope unit="page">55</biblScope></bibl>
	<bibl><title level="m">Box 9. Methods used in PMPRB price comparisons</title> <author>...............................................................................</author>. <biblScope unit="page">73 REFERENCES</biblScope></bibl>
	<bibl><author>Ackroyd-Stolarz, S., N. Hartnell, N.J. MacKinnon</author> (<date>2006</date>), &quot; <title level="a">Demystifying medication safety: Making sense ofterminology</title> &quot; , <title level="m">Research in Social and Administrative Pharmacy</title> ,Vol .<biblScope unit="volume">2</biblScope> ,pp .<biblScope unit="page">280-289</biblScope>.</bibl>
	<bibl><author>Anis, A. and Q. Wen</author> (<date>1998</date>), &quot; <title level="a">Price regulation of pharmaceuticals in Canada</title> &quot; , <title level="j">Journal of Health Economics</title>,Vol .<biblScope unit="volume">17</biblScope> ,pp .<biblScope unit="page">21 -38</biblScope>.</bibl>
	<bibl><author>Anis, A., D. Guh, X.H. Wang</author> (<date>2001</date>), &quot; <title level="a">A Dog&apos;s Breakfast: Prescription drug coverage varies widely across Canada</title>&quot; , <title level="j">Medical Care</title> ,Vol .<biblScope unit="volume">39</biblScope> ,No .<biblScope unit="issue">4</biblScope> .pp .<biblScope unit="page">315 -326</biblScope>.</bibl>
	<bibl><author>Anis, A., D. Guh, D. Lacaille, C. Marra, A. Rashidi, X. Li, J. Esdaile</author> (<date>2005</date>), &quot; <title level="a">When patients have to pay a shareof drug costs :effects on frequency of physician visits ,hospital admissions and filling of prescriptions</title> &quot;, <title level="j">Canadian Medical Association Journal</title> , Vol. <biblScope unit="volume">173</biblScope>, No. <biblScope unit="issue">11</biblScope>, pp. <biblScope unit="page">1335- 1340</biblScope>.</bibl>
	<bibl><author>Applied Management, Fraser Group and Tristat Resources</author>. (<date>2000</date>), <title level="a">Canadians&apos; access to insurance for prescriptionmedicines ,Volumes 1 :Range and extent of coverage</title> ,<note>submitted to Health Canada</note> .</bibl>
	<bibl><author>Applied Management, Fraser Group and Tristat Resources</author> (<date>2000</date>), <title level="a">Canadians&apos; access to insurance for prescriptionmedicines ,Volumes 2 :The un -insuredand under -insured</title>,<note>submitted to Health Canada</note> .</bibl>
	<bibl><author>Arthur, M., M. Hunt, and K. Lee</author> (<date>2006</date>), <title level="a">How Common are the Provincial/ Territorial Public Drug Formularies?,Poster Exhibition at Toward a National Pharmaceuticals Strategy</title> ,<pubPlace>Vancouver ,B .C.,Canadian Institutefor Health Information</pubPlace> , <date>February9 - 10,2006</date>.</bibl>
	<bibl><title level="j">Auditor General of British Columbia</title> (<date>2006</date>), <title level="a">Managing PharmaCare: slow progress toward Cost-effective druguse and a sustainable program</title> ,<publisher>British Columbia Ministry of Health</publisher> .</bibl>
	<bibl><title level="j">Auditor General of Canada</title> (<date>2004</date>), &quot; <title level="a">Chapter 4: Management of Federal Drug Benefit Programs</title> &quot; , <note>Report of theAuditor General to the House of Commons</note> ,<date>November 2004</date> .</bibl>
	<bibl><title level="j">Auditor General of Ontario</title> (<date>2001</date>), &quot; <title level="a">Audit of the Drug Programs Activity of the Ministry of Health and Long-TermCare</title> &quot; , <note type="report">Auditor Annual report</note> ,pp .<biblScope unit="page">189 -221</biblScope></bibl>
	<bibl><title level="j">BIOTECanada</title> (<date>2004</date>), <title level="a">Biotecanada orphan drug policy</title>, <note>Policy paper</note>, pp. <biblScope unit="page">6</biblScope>.</bibl>
	<bibl><title level="j">British Columbia College of Pharmacists</title> (<date>2004</date>), &quot; <title level="a">Drug interchangeability update</title> &quot; , <title level="j">FYI</title>, Vol.<biblScope unit="volume">3</biblScope>, No.<biblScope unit="issue">1</biblScope>, pp. <biblScope unit="page">4</biblScope>.</bibl>
	<bibl><title level="j">British Columbia Ministry of Health</title> (<date>2004</date>), <title level="m">PharmaCare Trends</title> <date>2003</date>, <pubPlace>Victoria</pubPlace>.</bibl>
	<bibl><author>Bruce, S., H. Prior, A. Katz, M. Taylor, S. Latosinsky, P. Martens, C. De Coster, M. Brownell, R. Soodeen andC .Steinbach</author> ( <date>2006</date>),<title level="a">Application of Patient Safety Indicators in Manitoba :A First Look</title> ,<publisher>Manitoba Centrefor Health Policy</publisher> .</bibl>
	<bibl><author>Campbell C., C. Cooke, S. Weerasinghe, I. Sketris, P. McLean-Veysey, C. Skedgel</author> (<date>2003</date>), &quot; <title level="a">Topical corticosteroidprescribing patterns following changes in drug benefit status</title> &quot; , <title level="j">The Annals of Pharmacotherapy</title> ,Vol. <biblScope unit="volume">37</biblScope>, pp. <biblScope unit="page">787- 793</biblScope>.</bibl>
	<bibl><title level="j">Canadian Organization for Rare Disorders</title> (<date>2005</date>), <title level="a">Towards a Canadian orphan drug policy</title>.</bibl>
	<bibl><title level="j">Canadian Institute for Health Information – CIHI</title>, (<date>2005</date>), <title level="a">Drug expenditure in Canada</title> <date>1985-2004</date>, <pubPlace>Ottawa</pubPlace>.</bibl>
	<bibl><title level="j">Canadian Institute for Health Information – CIHI</title>, (<date>2006</date>), <title level="a">Drug expenditure in Canada</title> <date>1985-2005</date>, <pubPlace>Ottawa</pubPlace>.</bibl>
	<bibl><title level="j">Canadian Medical Association</title> (<date>2003</date>), &quot; <title level="a">Principles for providing information about prescription drugs to consumers&quot; , statement approved by the Canadian Medical Association Board of Directors</title> ,<date>March 2003</date> .</bibl>
	<bibl><title level="j">Canadian Medical Association</title> (<date>2002</date>), &quot; <title level="a">Direct-to-Consumer Advertising Policy Statement</title> &quot; , <note>statement approvedby the CMA Board of Directors</note> ,<date>September 2002</date> .</bibl>
	<bibl><title level="j">Cancer Advocacy Coalition of Canada</title> (<date>2006</date>), <note>Report Card</note> <date>2005</date>, Vol. <biblScope unit="volume">8</biblScope>, pp. <biblScope unit="page">26-38</biblScope>.</bibl>
	<bibl><author>Cassels, A.</author> (<date>2002</date>), &quot; <title level="a">Paying for what works: BC&apos;s experience with the Reference Drug Program as a model forrational policy making</title> &quot; , <pubPlace>Vancouver</pubPlace> :<publisher>Canadian Centre for Policy Alternatives—BC Office .</publisher></bibl>
	<bibl><title level="j">Commission on the Future of Health Care in Canada</title> (<date>2002</date>), &quot; <title level="a">Chapter 9: prescription drugs</title> &quot; , <title level="j">Building on Values</title>( Finalreport ),pp .<biblScope unit="page">189 -210</biblScope>.</bibl>
	<bibl><author>Conseil du medicament</author> (<date>2005</date>), <title level="a">Rapport annuel de gestion</title> <date>2004-2005</date>, <orgName>Gouvernement du Québec</orgName>.</bibl>
	<bibl><author>Conseil du medicament</author> (<date>2006</date>), <title level="a">Rapport annuel de gestion</title> <date>2005-2006</date>, <orgName>Gouvernement du Québec</orgName>.</bibl>
	<bibl><author>Cooke C., L. Nissen, I. Sketris and S. Tett.</author> (<date>2005</date>), &quot; <title level="a">Quantifying the use of the statin antilipemic drugs: comparisonsand contrasts between Nova Scotia ,Canada and Queensland ,Australia</title> &quot; , <title level="j">Clinical Therapeutics</title> ,Vol. <biblScope unit="volume">27</biblScope>, No. <biblScope unit="issue">4</biblScope>, pp. <biblScope unit="page">497- 503</biblScope>.</bibl>
	<bibl><author>Danzon P.M. and M.F. Furukawa</author> (<date>2003</date>), &quot; <title level="a">Prices and availability of pharmaceuticals: Evidence from nine countries</title>&quot; , <title level="m">Health Affairs ,web exclusive</title> ,pp .<biblScope unit="page">W3 .521-536</biblScope>.</bibl>
	<bibl><author>D&apos;Cruz J., W. Hejazi and G. Fleischmann</author> (<date>2005</date>), &quot; <title level="a">Comparisons of retail prices of generic prescription drugsin Canada vs .United States :A comprehensive study</title> &quot; , <note>A Report Prepared for the Canadian Generic PharmaceuticalAssociation</note> .</bibl>
	<bibl><title level="j">EFPIA</title> (<title level="j">European Federation of Pharmaceutical Industries and Associations)</title> (<date>2005</date>), <title level="a">The Pharmaceutical Industryin Figures ,Key data – update</title> <date>2005</date> .</bibl>
	<bibl><author>Fraser Group</author>/ <title level="j">Tristat Resources</title> (<date>2002</date>), <title level="a">Drug expense coverage in the Canadian population: protection fromsevere drug expenses</title> .</bibl>
	<bibl><author>Gardner, D.M., B. Mintzes and A. Ostry</author> (<date>2003</date>), &quot; <title level="a">Direct-to-consumer prescription drug advertising in Canada:Permission by Default ?</title>&quot; <title level="j">Canadian Medical Association Journal</title> ,Vol .<biblScope unit="volume">169</biblScope> ,No .<biblScope unit="issue">5</biblScope> ,pp .<biblScope unit="page">425 -427</biblScope>.</bibl>
	<bibl><author>Government of Canada</author> (<date>2004</date>), &quot; <title level="a">Regulations amending the Food and Drug regulation (1390-data protection)</title>&quot; , <title level="j">Canada Gazette</title> ,Vol .<biblScope unit="volume">138</biblScope> ,No .<biblScope unit="issue">50</biblScope> .</bibl>
	<bibl><author>Government of Canada</author> (<date>2004</date>), &quot; <title level="a">Regulations amending the Patented Medicines (Notice of Compliance) Regulations</title>&quot; , <title level="j">Canada Gazette</title> ,Vol .<biblScope unit="volume">138</biblScope> ,No .<biblScope unit="issue">50</biblScope> .</bibl>
	<bibl><title level="m">Government of Canada. 39 th Parliament , 1 st Session Standing Committee on Health (HESA)</title>, <title level="a">Evidence frommeeting on Prescription Drugs House of Commons Standing Committee on Heath</title> ,<date>2006</date> ,http ://<ptr type="web">cmte.parl.gc.ca/cmte/CommitteePublication.aspx?SourceId=149490</ptr>.</bibl>
	<bibl><author>Government of Canada</author> (<date>2005</date>), &quot; <title level="a">Canada&apos;s winning secrets summary</title> &quot; , <ptr type="web">www.investincanada.gc.ca/en/1031/Canada_s_Winning_Secrets_Report.html,accessed 26</ptr> <date>May 2006</date> .</bibl>
	<bibl><author>Government of Ontario</author> (<date>2006</date>), <date>2004</date>/<date>2005</date> <note>Report Card for the Ontario Drug Benefit Program</note>.</bibl>
	<bibl><author>Grégoire J.P., P. Macneil, K. Skilton, J. Moisan, D. Menon, P. Jacobs, E. McKenzie and B. Ferguson</author> (<date>2001</date>),&quot; <title level="a">Inter -provincialvariation in Government drug formularies</title> &quot; , <title level="j">Canadian Journal of Public Health</title> ,Vol. <biblScope unit="volume">92</biblScope>, No. <biblScope unit="issue">4</biblScope>, pp. <biblScope unit="page">307- 312</biblScope>.</bibl>
	<bibl><author>Grootendorst, P &quot;</author><title level="a">Beneficiary Cost Sharing under Canadian Provincial Prescription Drug Benefit Programs: Historyand Assessment</title> ,&quot;<title level="j">Canadian Journal of Clinical Pharmacology</title> ,Vol .<biblScope unit="volume">9</biblScope> ,No .<biblScope unit="issue">2</biblScope> ,pp .<biblScope unit="page">79 –99</biblScope>.</bibl>
	<bibl><author>Grootendorst, P., L. Dolovitch, A.M. Holbrook, A.R. Levy and B.J. O&apos;Brien</author> (<date>2001</date>), &quot; <title level="a">The impact of referencepricing of cardiovascular drugs on health care costs and health outcomes :Evidence from British Columbia</title>&quot; , <note>Report for the Canadian Health Services Research Foundation</note> .</bibl>
	<bibl><author>Grootendorst, P., J.K. Marshall, A.M. Holbrook, L.R. Dolovitch, B.J. O&apos;Brien and A.R. Levy</author> (<date>2005</date>), &quot; <title level="a">The impactof reference pricing of nonsteroidal anti -inflammatoryagents on the use and costs of analgesic drugs</title>&quot; , <title level="j">Health Services Research</title> , Vol. <biblScope unit="volume">40</biblScope>, pp. <biblScope unit="page">1297- 1317</biblScope>.</bibl>
	<bibl><author>Grootendorst, P. and D. Stewart</author>, &quot; <title level="a">A re-examination of the impact of reference pricing on anti-hypertensive drugplan expenditures in British Columbia</title> &quot; , <title level="j">Health Economics</title> ,Vol .<biblScope unit="volume">15</biblScope>,pp .<biblScope unit="page">735 –742</biblScope>.</bibl>
	<bibl><author>Health Canada</author> (<date>2004</date>), <title level="a">Non-Insured Health Benefit Program – Annual report</title> <date>2003</date>/<date>2004</date>, <pubPlace>Ottawa</pubPlace>.</bibl>
	<bibl><author>Health Canada</author> (<date>2006</date>), <title level="a">Regulatory Review of Pharmaceuticals, Biologics and Medical Devices 2005 -AnnualSummary of Performance</title> ,<pubPlace>Ottawa</pubPlace> .</bibl>
	<bibl><author>Hollis, A. and Law, S.</author> (<date>2004</date>), &quot; <title level="a">A National Formulary for Canada</title> &quot; , <title level="j">Canadian Public Policy</title>, Vol. <biblScope unit="volume">30</biblScope>, No. <biblScope unit="issue">4</biblScope>,pp .<biblScope unit="page">445 -452</biblScope>.</bibl>
	<bibl><author>IMS Health</author> (<date>2006</date>), &quot; <title level="a">Prescription drug purchases by Canadian hospitals and pharmacies reach $16</title>.<biblScope unit="volume">57</biblScope> billionin <date>2005</date> &quot; , <ptr type="web">www .imshealth.com/web/content/0,3148,77303623_63872702_77770096_77808854,00.html,accessed24</ptr> <date>May2006</date> .</bibl>
	<bibl><author>IMS Health Canada</author> (<date>2006b</date>), <title level="m">IMS Drug Monitor: Canada</title>.</bibl>
	<bibl><author>IMS Health Canada</author> (<date>2006a</date>), &quot; <title level="a">Prescription drug purchases by Canadian hospitals and pharmacies reach $16.57billion in</title> <date>2005</date> &quot; , <title level="j">IMS Health</title> ( <date>2006b</date>)</bibl>
	<bibl><author>DELSA/HEA/WD/HWP</author>(<date>2006</date>)<biblScope unit="issue">4</biblScope></bibl>
	<bibl><biblScope unit="page">82</biblScope></bibl>
	<bibl><title level="j">Industry Canada – Life Sciences Branch</title> (<date>2006</date>), &quot; <title level="a">Canadian pharmaceutical industry profile</title> &quot; .</bibl>
	<bibl><author>Kaiser Family Foundation</author> (<date>2006</date>), &quot; <title level="a">Exhibit 1.19: Retail Prescriptions Filled at Pharmacies by State: PrescriptionsPer Capita and Retail Prescription Sales</title> ,<date>2004</date> &quot; , <title level="m">Trends and Indicators in the Changing HealthCare Marketplace</title> .</bibl>
	<bibl><author>Kephart G., I. Sketris, S. Bowles, M. Richard, C. Cooke</author> (<date>2005</date>), &quot; <title level="a">Impact of criteria-based reimbursement policyon the use of respiratory drugs delivered by nebuliser and health care services utilisation in Nova Scotia, Canada</title>&quot; , <title level="j">Pharmacotherapy</title> , Vol. <biblScope unit="volume">25</biblScope>, No. <biblScope unit="issue">9</biblScope>, pp. <biblScope unit="page">1248- 1257</biblScope>.</bibl>
	<bibl><title level="j">Legislative Assembly of Ontario</title> (<date>2006</date>), <title level="a">Bill 102: An Act to amend the Drug Interchangeability and DispensingFee Act and the Ontaro Benefit Act</title> ,<biblScope unit="volume">30 pages</biblScope> .</bibl>
	<bibl><author>Lexchin J.</author> (<date>2006</date>), &quot; <title level="a">A comparison of new drug availability in Canada and the United States and potential therapeuticimplications of differences</title> &quot; , <title level="j">Health Policy</title> ,Vol .<biblScope unit="volume">79</biblScope> ,No .<biblScope unit="issue">2 -3</biblScope>,pp .<biblScope unit="page">214 -220</biblScope>.</bibl>
	<bibl><author>Luffman J.</author> (<date>2005</date>), &quot; <title level="a">Out-of-pocket spending on prescription drugs</title> &quot; , <title level="j">Perspectives on Labour and Income</title>, Vol.<biblScope unit="volume">17</biblScope> ,No .<biblScope unit="issue">4</biblScope> ,<biblScope unit="page">pp 5 -13</biblScope>.</bibl>
	<bibl><author>Marchildon, G.P.</author> (<date>2005</date>), <title level="m">Health Systems in Transition: Canada, Copenhagen, WHO, Regional Office for Europeon behalf of the European Observatory on Health Systems and Policies</title> .</bibl>
	<bibl><author>Marchildon, G.P.</author> (<date>2006</date>), &quot; <title level="a">Federal pharmacare: prescription for an ailing federation?</title> &quot; , Inroads, No. <biblScope unit="issue">18</biblScope>, pp. <biblScope unit="page">94-108</biblScope>.</bibl>
	<bibl><author>Marshall J.K., P.V. Grootendorst, B.J. O&apos;Brien, L.R. Dolovitch, A.M. Holbrook and A.R. Levy</author> (<date>2002</date>), &quot;<title level="a">Impact of reference -basedpricing for histamine -2receptor antagonists and restricted access to proton pumpinhibitors in British Columbia</title> &quot; , <title level="j">Canadian Medical Association Journal</title> , Vol. <biblScope unit="volume">166</biblScope>, No. <biblScope unit="issue">13</biblScope>, pp.<biblScope unit="page">1655 -1662</biblScope></bibl>
	<bibl><author>McIntosh T.</author> (<date>2004</date>), &quot; <title level="a">National pharmacare proposal &quot; , Health Policy Monitor, Bertelsmann Foundation</title>, SurveyNo .<biblScope unit="issue">4</biblScope>.</bibl>
	<bibl><author>McKenzie, K.J.</author> (<date>2005</date>), &quot; <title level="a">Tax Subsidies for R&amp;D in Canadian Provinces</title>, &quot; <title level="j">Canadian Public Policy</title>, Vol. <biblScope unit="volume">XXXI</biblScope>,No .<biblScope unit="issue">1</biblScope> ,pp .<biblScope unit="page">29 -44</biblScope>.</bibl>
	<bibl><author>McMahon, M., S. Morgan, and C. Mitton</author> (<date>2006</date>), &quot; <title level="a">The common drug review: A NICE start for Canada?</title> &quot; , <title level="j">HealthPolicy</title> ,Vol .<biblScope unit="volume">77</biblScope> ,No .<biblScope unit="issue">3</biblScope> ,pp .<biblScope unit="page">339 -351</biblScope>.</bibl>
	<bibl><author>Mintzes, B., M.L. Barer, R.L. Kravitz, K. Bassett, J. Lexchin, A. Kazanjian, R.G. Evans, R. Pan, and S.A. Marion</author>( <date>2003</date>),&quot; <title level="a">How does direct -to-consumeradvertising ( DTCA)affect prescribing ?A survey in primary careenvironments with and without DTCA</title> &quot; , <title level="j">Canadian Medical Association Journal</title> , Vol. <biblScope unit="volume">169</biblScope>. No.<biblScope unit="issue">5</biblScope> ,pp .<biblScope unit="page">405 -412</biblScope> .</bibl>
	<bibl><author>Morgan, S., M. Barer, and J.D. Agnew</author> (<date>2003</date>), &quot; <title level="a">Whither Seniors&apos; Pharmacare: Lessons from (and for) Canada</title>&quot; , <title level="j">Health Affairs</title> ,Vol .<biblScope unit="volume">22</biblScope> ,No .<biblScope unit="issue">3</biblScope> ,pp .<biblScope unit="page">49 -59</biblScope>.</bibl>
	<bibl><author>Morgan S., A. Kozyrskyj, C. Metge, N. Roos and M.Dahl</author> (<date>2003</date>), <title level="m">Pharmaceuticals: Therapeutic Interchangeand Pricing Policies</title> ,<orgName>Manitoba Centre for Health Policy ,Manitoba Health</orgName> .</bibl>
	<bibl><author>Morgan, S.</author> (<date>2004</date>), &quot; <title level="a">Drug spending in Canada: recent trends and causes</title> &quot; , <title level="j">Medical Care</title>, Vol. <biblScope unit="volume">42</biblScope>, No. <biblScope unit="issue">7</biblScope>, pp.<biblScope unit="page">635 -642</biblScope>.</bibl>
	<bibl><author>Morgan, S., K. Basset, B. Mintzes</author> (<date>2004</date>), &quot; <title level="a">Outcome-based drug coverage in British Columbia</title> &quot; , <title level="j">Health Affairs</title>,Vol .<biblScope unit="volume">23</biblScope> ,No .<biblScope unit="issue">3</biblScope> ,pp .<biblScope unit="page">269 -276</biblScope>.</bibl>
	<bibl><author>Morgan, S., M. McMahon, J. Lam, D. Mooney, and C. Raymond</author> (<date>2005</date>), <title level="a">The Canadian Rx Atlas, The Centrefor Health Services and Policy Research</title> ,<pubPlace>Vancouver</pubPlace> .</bibl>
	<bibl><title level="j">MSSS</title> (<title level="a">Ministère de la santé et des services sociaux)</title> (<date>2004</date>), <title level="m">Politique du médicament</title>, <note>Document de consultation</note>.</bibl>
	<bibl><author>Murphy A., N. MacKinnon, P. Flanagan, S. Bowles and I. Sketris</author> (<date>2005</date>), &quot; <title level="a">Pharmacists&apos; participation in an inhaledrespiratory medication program :Reimbursement of professional fees</title> &quot; , <title level="j">Annals of Pharmacotherapy</title> ,Vol. <biblScope unit="volume">39</biblScope>, pp. <biblScope unit="page">655- 661</biblScope>.</bibl>
	<bibl><title level="a">National Institute for Health Care Management Foundation</title> (<date>2001</date>), <title level="m">Prescription Drugs and Mass Media Advertising</title>,<date>2000</date> ,<title level="a">The National Institute for Health Care Management Research and Educational Foundation</title> ,<pubPlace>Washington</pubPlace>.</bibl>
	<bibl><title level="j">OECD</title> (<date>2005</date>), <title level="m">OECD Health Data 2005: Statistics and Indicators for 30 Countries</title>, <pubPlace>Paris</pubPlace>.</bibl>
	<bibl><title level="j">OECD</title> (<date>2006</date>), <title level="m">OECD Economic Survey: Canada</title>, <pubPlace>Paris</pubPlace>.</bibl>
	<bibl><title level="j">Ontario Ministry of Health and Long Term Care</title> (<date>2006</date>), <date>2004</date>/05 <note>Report Card for the Ontario Drug BenefitProgram</note> .</bibl>
	<bibl><author>Palmer d&apos;</author><title level="j">Angelo Consulting Inc.</title> (<date>2002</date>), <title level="m">Generic drug prices: A Canada US comparison</title>.</bibl>
	<bibl><author>Palumbo B.F.</author> (<date>2004</date>) &quot; <title level="a">Status of legislation on pharmaceutical reimportation: The relevance of IP laws to reimportation</title>&quot; , <title level="j">Managed Care</title> ,Vol .<biblScope unit="volume">13</biblScope> ,No .<biblScope unit="issue">6</biblScope>,pp .<biblScope unit="page">3 -6</biblScope>.</bibl>
	<bibl><title level="j">PICTF (Pharmaceutical Industry Competitiveness Task Force)</title> (<date>2006</date>), <title level="m">Competitiveness and performance indicators</title><date>2005</date> .</bibl>
	<bibl><title level="m">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2001</date>), <title level="a">Provincial drug plans overview reports – PharmaceuticalTrends</title> <date>1995</date> /<biblScope unit="volume">96</biblScope>– <date>1999</date> /<biblScope unit="volume">00</biblScope>,<note>Report prepared by PMPRB for the F /P/TWorking group ondrug prices</note> , <pubPlace>Ottawa</pubPlace>.</bibl>
	<bibl><title level="j">PMPRB</title> (<title level="j">Patented Medicine Prices Review Board)</title> (<date>2002</date>), <title level="a">A study of the prices of the Top selling multiple sourcemedicines in Canada ,prepared by PMPRB for the</title> F /P/TWorking group on drug prices ,<pubPlace>Ottawa</pubPlace> .</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2002</date>), <title level="a">Verification of foreign patented drug prices</title>, <pubPlace>Ottawa</pubPlace>.</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2002a</date>), <title level="a">Foreign Price trends for patented medicines</title>, <pubPlace>Ottawa</pubPlace>.</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2002b</date>), <title level="a">A comparison of pharmaceutical Research &amp; DevelopmentSpending in Canada and selected countries</title> ,<pubPlace>Ottawa</pubPlace> .</bibl>
	<bibl><title level="j">PMPRB</title> (<title level="j">Patented Medicine Prices Review Board)</title> (<date>2003</date>), <title level="a">Top selling non-patented single source drug products:international comparison</title> <date>1998</date> /<date>1999</date>,<note>prepared by PMPRB for the F /P/TWorking group on drugprices</note> , <pubPlace>Ottawa</pubPlace>.</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2003</date>) <title level="a">Compendium of Guidelines, Policies and procedures</title>,<pubPlace>Ottawa</pubPlace> .</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2005a</date>), <title level="m">Annual Report</title> <date>2004</date>, <pubPlace>Ottawa</pubPlace>.</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2005b</date>), <title level="a">Budget impact analysis guidelines: Needs assessment</title>,<pubPlace>Ottawa</pubPlace> .</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2005c</date>), <title level="a">The impact upon public drug plans of changes indrug distribution</title> ,<pubPlace>Ottawa</pubPlace> .</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2006a</date>), <title level="m">Annual Report 2005</title>, <pubPlace>Ottawa</pubPlace>.</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2006b</date>), <note type="report">Pharmaceutical trends – Overview report</note>, <title level="j">AnalyticalStudy Series</title> ,<pubPlace>Ottawa</pubPlace> .</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2006c</date>), <title level="a">Non-patented prescription drug prices reporting– Canadian and Foreign Price trends</title> ,<pubPlace>Ottawa</pubPlace> .</bibl>
	<bibl><title level="j">PMPRB (Patented Medicine Prices Review Board)</title> (<date>2006d</date>), <title level="a">Discussion guide for the consultations on the Board&apos;sexcessive price guidelines</title> ,<pubPlace>Ottawa</pubPlace> .</bibl>
	<bibl><author>Paterson M., K. Bassett, M. Mamdani, J. Wright, G. Naglie, A. Laupacis, G. Anderson</author> (<date>2003</date>), &quot; <title level="a">What effectsdo provincial drug plan policies for new drugs have on patterns of use and cost ?</title>&quot; , <orgName>Institute for ClinicalEvaluative Science</orgName> .</bibl>
	<bibl><author>PausJenssen A.M., P.A. Singer, A.S. Detsky.</author> (<date>2003</date>), &quot; <title level="a">Ontario&apos;s formulary committee: How recommendationsare made ?</title>&quot; , <title level="j">Pharmacoeconomics</title> ,Vol .<biblScope unit="volume">21</biblScope> ,No .<biblScope unit="issue">4</biblScope> ,pp .<biblScope unit="page">285 -294</biblScope>.</bibl>
	<bibl><title level="j">Pharmaceutical Advertising Advisory Board</title> (<date>2006</date>), <title level="m">PAAB Review</title>.</bibl>
	<bibl><author>Priest L.</author> (<date>2006</date>), &quot; <title level="a">Drugs makers expected to shun Canada</title> &quot; , <title level="a">The Globe and Mail</title>, <date>June 23, 2006</date>.</bibl>
	<bibl><title level="j">Public Policy Forum</title> (<date>2006</date>), <title level="a">Generic Pharmaceuticals and Sector Development -Industry Challenges and PotentialSolutions</title> .</bibl>
	<bibl><author>Schneeweiss, S, A.M. Walker, R.J. Glynn, M. Maclure, C. Dormuth, and S.B. Soumerai</author> (<date>2002a</date>), &quot;<title level="a">Outcome of reference pricing for angiotensin -convertingenzyme inhibitors</title> &quot; , <title level="j">New England Journal of Medicine</title>, Vol. <biblScope unit="volume">346</biblScope>, No. <biblScope unit="issue">11</biblScope>, pp. <biblScope unit="page">822- 829</biblScope>.</bibl>
	<bibl><author>Schneeweiss, S., S.B. Soumerai, R.J. Glynn, M. Maclure, C. Dormuth and A.M. Walker</author> (<date>2002b</date>), &quot; <title level="a">Impact ofreference -basedpricing for angiotensin -convertingenzyme inhibitors on drug utilization</title> &quot; , <title level="j">Canadian MedicalAssociation Journal</title> , Vol. <biblScope unit="volume">166</biblScope>, No. <biblScope unit="issue">6</biblScope>, pp. <biblScope unit="page">737- 745</biblScope>.</bibl>
	<bibl><author>Schneeweiss S., S.B. Soumerai, M. Maclure, C. Dormuth, A.M. Walker, and R.J. Glynn</author> (<date>2003</date>), &quot; <title level="a">Clinical andeconomic consequences of reference pricing for dihydropyridine calcium channel blockers</title> &quot; , <title level="j">Clinical Pharmacology&amp; Therapeutics</title> , Vol. <biblScope unit="volume">74</biblScope>, pp. <biblScope unit="page">388- 400</biblScope>.</bibl>
	<bibl><author>Schneeweiss S., C. Dormuth, P. Grootendorst, S.B. Soumerai, and M. Maclure</author> (<date>2004</date>), &quot; <title level="a">Net health plan savingsfrom reference pricing for angiotensin -convertingenzyme inhibitors in elderly British Columbia residents</title>&quot; , <title level="j">Medical Care</title> , Vol. <biblScope unit="volume">42</biblScope>, No. <biblScope unit="issue">7</biblScope>, pp. <biblScope unit="page">653- 660</biblScope></bibl>
	<bibl><author>Schoen C., R. Osborn, P. Trang Huynh, M. Doty, K. Zapert, J. Peugh and K. Davis</author> (<date>2005</date>), &quot; <title level="a">Taking the pulseof health care systems :experiences of patients with health problems in six countries</title> &quot; , <title level="m">Health Affairs ,Web- exclusive</title>,pp. <biblScope unit="page">w5- 509-525</biblScope>.</bibl>
	<bibl><author>Sketris I., C. Metge, J. Ross, M. MacCara, D. Comeau, G. Kephart and J. Blackburn J.</author> (<date>2004a</date>), &quot; <title level="a">The use ofthe World Health Organisation Anatomical Therapeutic Chemical /Defined daily dose methodology inCanada</title> &quot; , <title level="j">Drug Information Journal</title> , Vol. <biblScope unit="volume">38</biblScope>, pp. <biblScope unit="page">1- 13</biblScope>.</bibl>
	<bibl><author>Sketris I., C. Metge, Y. Schevchuk, D. Comeau, G. Kephart, J. Blackburn, M. MacCara and A. Laturnas</author> (<date>March2004b</date> ),&quot; <title level="a">Comparison of anti -infectivedrug use in elderly persons in Manitoba</title> ,<pubPlace>Nova Scotia ,and Saskatchewan, Canada</pubPlace>: <title level="a">Relationshipto drug insurance reimbursement policies</title> &quot; , <title level="j">The American Journal of GeriatricPharmacotherapy</title> , Vol .<biblScope unit="volume">2</biblScope> ,No .<biblScope unit="issue">1</biblScope> ,pp .<biblScope unit="page">24 -35</biblScope> .</bibl>
	<bibl><author>Sketris, I., G. Kephart, D. Frail, C. Skedgel, and M. Allen</author> (<date>2004c</date>), &quot; <title level="a">The effects of deinsuring chlorpropamideon the prescribing of oral antihyperglycemics for Nova Scotia Seniors Pharmacare beneficiaries</title> &quot;, <note type="report">Pharmacotherapy</note> , Vol. <biblScope unit="volume">24</biblScope>, No. <biblScope unit="issue">6</biblScope>, pp. <biblScope unit="page">784- 791</biblScope>.</bibl>
	<bibl><author>Sketris, I., G. Kephart, C. Cooke, C. Skedgel, P. McLean-Veysey</author> (<date>2005</date>), &quot; <title level="a">Use of Physician Profiles to influenceprescribing of topical corticosteroids</title> &quot; , <title level="j">Canadian Journal of Clinical Pharmacology</title> ,Vol .<biblScope unit="volume">12</biblScope> ,No. <biblScope unit="issue">2</biblScope>, pp. <biblScope unit="page">186- 197</biblScope>.</bibl>
	<bibl><author>Skinner B.J.</author> (<date>2004</date>), <title level="a">Generic Drugopoly: Why Non-patented Prescription Drugs Cost More in Canada thanin the United States and Europe .The Fraser Institute</title> ,<pubPlace>Vancouver</pubPlace> .</bibl>
	<bibl><author>Skinner, B.J.</author> (<date>2005</date>), <title level="a">Canada&apos;s Drug Price Paradox: The Unexpected Losses Caused by Government Interferencein Pharmaceutical Markets .Fraser Institute digital publication ,The Fraser Institute</title> ,<pubPlace>Vancouver</pubPlace> .</bibl>
	<bibl><author>Skinner, B.J.</author> (<date>2006</date>), <title level="a">Price Controls, Patents, and Cross-Border Internet Pharmacies: Risks to Canada&apos;s DrugSupply and International Trading Relations</title> .<title level="j">Critical Issues Bulletin</title> ,<pubPlace>The Fraser Institute ,Vancouver</pubPlace> .</bibl>
	<bibl><title level="m">Standing Senate Committee on Social Affairs</title> (<date>2002</date>), <title level="a">Science and Technology, The Health of Canadians – TheFederal Role ,Final Report</title> ,Chapter <biblScope unit="volume">7</biblScope> ,http ://<ptr type="web">www.parl.gc.ca/37/2/parlbus/commbus/senate/Com-e/soci-e/rep-e/repoct02vol6-e.htm,accessed</ptr><date>May 2006</date>.</bibl>
	<bibl><author>Smith M.</author> (<date>1993</date>), <title level="a">Patent protection for pharmaceutical products, Government of Canada, Law and GovernmentDivision</title> ,http ://<ptr type="web">dsp-psd.pwgsc.gc.ca</ptr>/Collection-R/LoPBdP/BP/<note>bp354-e.htm,accessed 1</note> <date>May2006</date> .</bibl>
	<bibl><author>Statistics Canada</author> (<date>2006</date>), &quot; <title level="a">Estimates of total spending on research and development in the health field in Canada</title>&quot; , <title level="j">Sciences Statistics ,Service Bulletin</title> ,Vol .<biblScope unit="volume">30</biblScope> ,No .<biblScope unit="issue">3</biblScope> .</bibl>
	<bibl><author>Tamblyn, R, R. Laprise, J.A. Hanley, M. Abrahamowicz, S. Scott, N. Mayo, J. Hurley, R. Grad, E. Latimer,R .Perreault ,P .McLeod ,A .Huang ,P .Larochelle and L .Mallet</author> ( <date>2001</date>),&quot; <title level="a">Adverse Events Associated WithPrescription Drug Cost - SharingAmongPoor and Elderly Persons</title> &quot; , <title level="j">JAMA</title> , Vol. <biblScope unit="volume">285</biblScope>, No.<biblScope unit="issue">4</biblScope> ,pp .<biblScope unit="page">421 -429</biblScope></bibl>
	<bibl><orgName>University of Calgary</orgName> (<date>2004</date>), <title level="a">A national formulary for Canada</title>, <note>working paper</note>.</bibl>
	<bibl><author>DELSA/HEA/WD/HWP</author>(<date>2006</date>)<biblScope unit="issue">4</biblScope></bibl>
	<bibl><biblScope unit="page">86</biblScope></bibl>
	<bibl><orgName>US Department of Commerce</orgName> (<date>2004</date>), <title level="a">NAFTA 10 Years Later, International Trade Administration</title>, <publisher>Office ofIndustry Trade Policy ,</publisher><author>Vandergrift ,M. andP . Kanavos</author>( <date>1997</date> ),&quot;<title level="a">Health policy versus industrial policy in the pharmaceutical sector : thecaseof Canada</title> &quot; , <title level="j">Health Policy</title> , Vol .<biblScope unit="volume">41</biblScope> ,pp .<biblScope unit="page">241 -260</biblScope> .</bibl>
	<bibl><author>Vekeman, G.</author> (<date>2005</date>), &quot; <title level="a">L&apos;industrie pharmaceutique dans l&apos;Union Européenne</title> &quot; , <title level="m">Statistiques en bref, Industrie,commerce et services ,Communautés Européennes</title> .</bibl>
	<bibl><author>Wagner W.J.</author> (<date>2004</date>), &quot; <title level="a">The Relevance of Intellectual Property Laws to Reimportation</title> &quot; , <title level="j">Managed Care, supplement</title>,Vol .<biblScope unit="volume">13</biblScope> ,No .<biblScope unit="issue">6</biblScope> supplement ,pp .<biblScope unit="page">20 -22</biblScope></bibl>
	<bibl><author>Mossialos, M. Mrazek and T. Walley</author> (eds.) (<date>2004</date>), &quot; <title level="a">Financial incentives and prescribing</title> &quot; , in <title level="m">RegulatingPharmaceuticals in Europe :Striving for Efficiency ,Equity and Quality</title> ,<publisher>Open University Press</publisher> ,<pubPlace>Maidenhead</pubPlace>.</bibl>
	<bibl><author>Ward, C.</author> (<date>2004</date>), &quot; <title level="a">Economic and Policy Implications of Reimportation: A Canadian Perspective</title>, &quot; <title level="j">ManagedCare</title> ,Vol .<biblScope unit="volume">13 .No .supplement 3</biblScope> ,pp .<biblScope unit="page">17 -20</biblScope>.</bibl>
	<bibl><author>Wilson R.</author> (<date>2001</date>) &quot; <title level="a">Quality improvement will require a major commitment</title> &quot; , <title level="j">Hospital Quarterly</title>, Vol. <biblScope unit="volume">4</biblScope>, No.<biblScope unit="issue">3</biblScope> ,pp .<biblScope unit="page">20 -24</biblScope>.</bibl>
	<bibl><author>DELSA/HEA/WD/HWP</author>(<date>2006</date>)<biblScope unit="issue">4</biblScope></bibl>
	<bibl><author>87 OECDHEALTH WORKING PAPERS Papers</author> in<title level="m">this series can be found on the OECD website : www. oecd.org</title>/els/health/workingpapersNo. <biblScope unit="issue">23</biblScope><author>HEALTHCARE QUALITY INDICATORS PROJECT , CONCEPTUAL FRAMEWORKPAPER</author> ( <date>2006</date> ) EdwardKelleyandJeremy Hurst No . <biblScope unit="issue">22</biblScope> HEALTH <title level="j">CAREQUALITYINDICATORS PROJECT , INITIAL INDICATORS REPORT</title> (<date>2006</date> ) <author>Soeren Mattke ,EdwardKelley ,Peter Scherer, Jeremy Hurst, Maria LuisaGil Lapetra andthe HCQI</author> Expert Group Members No . <biblScope unit="issue">21</biblScope><title level="j">THE SUPPLY OF PHYSICIANS INOECDCOUNTRIES</title> ( <date>2006</date> ) <author>Steven Simeons and Jeremy Hurst</author> No.<biblScope unit="issue">20</biblScope> <author>CONSUMER DIRECTION AND CHOICE INLONG -TERMCARE FOR OLDER PERSONS , INCLUDING PAYMENTS FORINFORMALCARE : HOW CAN ITHELP IMPROVECARE OUTCOMES , EMPLOYMENT ANDFISCAL SUSTAINABILITY ?</author> ( <date>2005</date> ) <title level="m">Jens LundsgaardNo. 19 TACKLING NURSE SHORTAGESIN OECDCOUNTRIES</title>( <date>2004</date> ) <author>StevenSimoens, Mike Villeneuve and Jeremy Hurst No</author> . <biblScope unit="issue">18</biblScope><author>PRIVATEHEALTH INSURANCE INTHE NETHERLANDS .A CASE STUDY</author> ( <date>2004</date>)<note>Nicole Tapay and Francesca Colombo No . 17SKILL -</note> <author>MIX AND POLICYCHANGEIN THE HEALTHWORKFORCE</author> : <title level="j">NURSES IN ADVANCEDROLES</title>( <date>2004</date> )<author>JamesBuchan and Lynn Calman</author> No . <biblScope unit="issue">16</biblScope> <author>SHA- BASED NATIONAL HEALTHACCOUNTS IN THIRTEENOECDCOUNTRIES</author> : <title level="j">A COMPARATIVE ANALYSIS</title> ( <date>2004</date>)<editor>Eva Orosz andDavidMorgan</editor> No . <biblScope unit="issue">15</biblScope> <title level="j">PRIVATE HEALTH INSURANCE INOECD COUNTRIES :THE BENEFITS ANDCOSTSFOR INDIVIDUALS AND HEALTH SYSTEMS</title> ( <date>2004</date>)<note type="report">Francesca Colombo and Nicole Tapay No . 14INCOME - RELATED INEQUALITY IN THE USEOF MEDICAL CARE IN 21OECDCOUNTRIES</note> ( <date>2004</date> ) <note>Eddy van Doorslaer,Cristina Masseria andtheOECD Health Equity Research Group No . 13 DEMENTIA CARE IN 9OECD COUNTRIES:A COMPARATIVE ANALYSIS</note> (<date>2004</date> ) <orgName>Pierre Moise , Michael Schwarzinger , Myung- Yong Umandthe Dementia Experts &apos; Group</orgName> <note type="report">No . 12PRIVATE HEALTH INSURANCE IN FRANCE(2004 ) ThomasC. Buchmueller andAgnes CouffinhalNo. 11 THE SLOVAK HEALTH INSURANCESYSTEM AND THEPOTENTIALROLE FOR PRIVATE HEALTH INSURANCE : POLICY CHALLENGES(2004 ) FrancescaColombo and Nicole Tapay No. 10PRIVATEHEALTH</note> <author>INSURANCE IN IRELAND . A CASE STUDY</author> ( <date>2004</date> ) <pubPlace>Francesca Colombo andNicole TapayNo . 9 HEALTHCARESYSTEMS</pubPlace> : <title level="j">LESSONS FROM THE REFORM EXPERIENCE</title>(<date>2003</date> ) <pubPlace>Elizabeth Docteur and Howard OxleyNo . 8 PRIVATE HEALTHINSURANCEIN AUSTRALIA . A CASESTUDY</pubPlace> ( <date>2003</date>)<note>Francesca Colombo andNicole Tapay No. 7 EXPLAINING WAITING - TIMES VARIATIONSFORELECTIVE SURGERY ACROSSOECD COUNTRIES</note> ( <date>2003</date> )<note>LuigiSiciliani and JeremyHurst No . 6 TACKLINGEXCESSIVE WAITING TIMES FOR ELECTIVESURGERY: A COMPARISON OFPOLICIES IN 12 OECDCOUNTRIES</note>( <date>2003</date> )<publisher>Jeremy HurstandLuigi Siciliani</publisher></bibl>

		</listBibl>
	</back>
	</text>
</TEI>
